Updated tablet formula combines 24 mg of zinc with a 1,458 mg multi-botanical blend; company publishes research context covering zinc, cordyceps, reishi, amla, Arjuna and additional plant-derived ingredients
VANCOUVER, British Columbia, September 25, 2026 — Leading Edge Health announced the U.S. launch of Volume Pills, a dietary supplement for adult men that combines zinc with a multi-botanical blend in tablet form.
Published Supplement Facts information lists 24 mg of zinc and a 1,458 mg botanical blend per two-tablet serving. Ingredients identified within the blend include Arjuna, Ling Zhi, Emblica officinalis, Fucus vesiculosus, Rou Gui, Tian Men Dong, Xian Mao, Dong Chong Xia Cao, Ku Gua, Hong Hua Fen and additional plant-derived components.
As part of the product announcement, Leading Edge Health is providing research context for selected ingredients while emphasizing that studies conducted on individual botanicals do not establish the effects of the complete Volume Pills formulation.
“The formula brings together ingredients with very different research histories, so it is important to distinguish what has been studied independently from what has been demonstrated for the finished product,” said Kevin Shaw, Product Head at Volume Pills. “Published studies typically use defined preparations and doses, while the botanical ingredients in Volume Pills are listed within a combined blend. Those differences need to remain clear when discussing the research.”
A Multi-Ingredient Men’s Wellness Formula
Volume Pills are supplied as tablets with a listed serving size of two tablets. According to publicly available label information, zinc is disclosed separately at 24 mg per serving, while the botanical ingredients are combined within a 1,458 mg proprietary blend.
That distinction is important when examining scientific literature. Controlled studies generally identify a specific ingredient or standardized preparation, the amount administered, the characteristics of study participants, the study duration and the outcomes being measured.
Published research on single botanicals provides valuable scientific context regarding the properties of individual components. While study results on isolated ingredients offer supportive background on the formula’s key constituents, they reflect independent research rather than clinical evaluation of the multi-ingredient Volume Pills formulation as a whole.
Zinc: Established Nutritional Role With Defined Intake Guidelines
Zinc is the component of the formula for which an individual quantity is publicly disclosed. The label lists 24 mg of zinc per two-tablet serving.
Zinc is an essential mineral involved in numerous physiological processes. The National Institutes of Health Office of Dietary Supplements states that zinc participates in cellular metabolism and is required for the activity of hundreds of enzymes. It also contributes to protein synthesis, DNA synthesis, cell signaling, wound healing and normal immune function. The NIH lists a Recommended Dietary Allowance of 11 mg per day for adult men and a tolerable upper intake level of 40 mg per day for adults from food and dietary supplements combined.
The 24 mg contained in Volume Pills should therefore be evaluated as part of a person’s total daily zinc intake.
For more information, visit the official website VolumePills.com.
Consumers taking multivitamins or other zinc-containing products should review the combined amount. The NIH notes that prolonged intake of 50 mg or more of supplemental zinc per day can interfere with copper absorption. Zinc may also interact with certain medicines, including quinolone and tetracycline antibiotics and penicillamine.
These established nutritional functions and intake guidelines provide context for the zinc content of the formula but do not establish a specific result from Volume Pills.
Dong Chong Xia Cao: Controlled Research Has Produced Mixed Findings
Dong Chong Xia Cao is a traditional name associated with cordyceps. Cordyceps preparations have been investigated in controlled human research, including studies examining physical performance and fatigue-related measures. Findings vary depending on the preparation, participant population and amount studied.
A randomized controlled trial involving 22 trained male cyclists evaluated 3 grams per day of CordyMax Cs-4 for five weeks. Researchers measured aerobic capacity, ventilatory threshold and endurance time-trial performance.
The study found no significant improvement in aerobic capacity or endurance performance compared with placebo. The result is relevant because it demonstrates why the presence of a traditional botanical should not automatically be interpreted as evidence of a measurable effect.
It also demonstrates the importance of dose comparisons. The study evaluated 3 grams per day of a specific cordyceps preparation. Volume Pills does not separately disclose the amount of Dong Chong Xia Cao contained within its 1,458 mg botanical blend.
The findings therefore cannot be transferred directly to Volume Pills, whether the result of the individual study is positive, neutral or negative.
Ling Zhi: Traditional Use and Human Evidence Should Be Considered Separately
Ling Zhi generally refers to reishi mushroom, scientifically known as Ganoderma lucidum. Reishi has a long history of use in East Asian traditional practices. Modern scientific research has examined compounds found in reishi, including beta-glucan polysaccharides and triterpenes.
However, evidence differs considerably according to the preparation and purpose being studied. Memorial Sloan Kettering Cancer Center notes that reishi has been investigated in several areas but also identifies important safety considerations.
Reported adverse effects can include nausea and difficulty sleeping, and rare liver injury has been reported. Reishi may also interact with certain medications. Memorial Sloan Kettering advises additional caution for people taking anticoagulant or antiplatelet medicines because reishi may increase bleeding risk. It also identifies potential concerns for people using immunosuppressive medicines.
The amount of Ling Zhi present in Volume Pills is not individually disclosed in the available label information. Research involving isolated Ganoderma lucidum preparations should therefore be considered scientific background about the ingredient rather than evidence regarding the complete Volume Pills formula.
Emblica Officinalis: Small Human Trial Provides Ingredient Context
Emblica officinalis, commonly known as amla or Indian gooseberry, is another plant-derived ingredient identified in the Volume Pills formula. A randomized, double-blind, crossover, placebo-controlled study evaluated an amla preparation in 15 healthy adults.
Participants received 500 mg per day, and researchers examined several measurements related to vascular function, blood markers, oxidative stress, glucose and lipid profiles. Changes were observed in several measured biomarkers during the study. However, the trial had notable limitations when considered in relation to Volume Pills.
Only 15 participants were included, the researchers evaluated a specific amla preparation independently, and the investigation did not involve the combination of ingredients used in Volume Pills. In addition, the individual quantity of Emblica officinalis within the Volume Pills proprietary blend is not disclosed.
The study can therefore help describe the scientific research surrounding amla but cannot establish what effect, if any, that ingredient has within the finished Volume Pills formulation.
Arjuna: Studies Use Defined Preparations and Specific Populations
Arjuna generally refers to Terminalia arjuna, a tree whose bark has a history of use in traditional Indian wellness practices. Several human studies have investigated Terminalia arjuna preparations.
One randomized placebo-controlled trial involved 105 adults with coronary heart disease. Participants were assigned to placebo, vitamin E or 500 mg per day of Terminalia arjuna bark powder. Researchers examined lipid measurements and oxidative-stress markers after 30 days.
Another controlled investigation evaluated Terminalia arjuna in adults with stable coronary artery disease using 500 mg twice daily alongside existing medical treatment.
These studies are useful for understanding how specific Arjuna preparations have been investigated, but they also illustrate why study populations matter. The participants had diagnosed cardiovascular conditions and were studied under controlled medical protocols. Those findings cannot be generalized to healthy adults taking a multi-ingredient wellness supplement.
Volume Pills also does not disclose how much Arjuna is contained within its combined botanical blend. Leading Edge Health therefore does not attribute findings from these trials to the finished Volume Pills formulation.
Fucus Vesiculosus: Seaweed Source Requires Attention to Iodine Variability
Fucus vesiculosus, commonly known as bladderwrack, is a brown seaweed. Seaweeds can contain iodine, an essential trace mineral required for normal thyroid hormone production.
The NIH Office of Dietary Supplements notes that iodine concentrations vary considerably among different seaweed species and products. This variation is important because the name of a seaweed ingredient alone does not establish the amount of iodine supplied by a finished supplement.
The NIH lists an adult tolerable upper intake level of 1,100 micrograms of iodine per day from food and supplements.
Both inadequate and excessive iodine intake can influence thyroid function. The available Volume Pills label information does not separately identify the amount of Fucus vesiculosus in the botanical blend or specify an iodine quantity attributable to that ingredient.
People managing thyroid conditions, taking thyroid medication or using additional iodine-containing supplements should discuss their total intake with a qualified healthcare professional.
Additional Botanical Ingredients
Volume Pills also identifies several other botanical and plant-derived components. Rou Gui is generally associated with cinnamon bark. Research on cinnamon varies according to species, preparation and dose, and findings from one preparation should not automatically be applied to another.
Ku Gua is commonly associated with bitter melon. Human research has primarily examined bitter melon in metabolic contexts, with varying results across different preparations and study populations. Xian Mao is a traditional botanical used in Chinese and Indian systems. Much of the available literature concerns traditional use, laboratory research or animal models rather than large controlled human trials.
Tian Men Dong is another botanical with a history of traditional use. Its historical use should be distinguished from evidence derived from modern controlled trials. Hong Hua Fen is a plant-derived ingredient traditionally used in botanical preparations.
4′,5,7-Trihydroxyflavone is a flavonoid compound identified within the formula. Solidilin and Drilizen are proprietary ingredient names appearing in Volume Pills product information.
The available Supplement Facts information does not provide separate quantities for these components. For that reason, their inclusion in the formula should not be presented as evidence that the finished product reproduces results associated with an isolated botanical, compound or experimental preparation.
What Ingredient Research Does and Does Not Show
The Volume Pills research overview separates three questions: what an ingredient is, what researchers have independently found when studying it and what has been demonstrated for the complete Volume Pills formulation. Those questions are not interchangeable.
Some ingredients, particularly zinc, have clearly established nutritional functions and defined intake recommendations. Other components have human research but were evaluated as isolated preparations at specific doses and in specific populations.
Still others have evidence based primarily on traditional use, laboratory experiments, animal research or relatively small human investigations. The complete Volume Pills formula combines numerous ingredients, while the individual quantities within its 1,458 mg botanical blend are not publicly disclosed.
No individual-ingredient study referenced in this release should therefore be interpreted as a clinical trial of Volume Pills. “A study involving 500 mg of one botanical cannot tell us what that ingredient contributes when its individual amount within a combined blend is not disclosed,” Shaw said. “That is why the research overview reports the study dose and population alongside the findings rather than applying those findings directly to Volume Pills.”
Safety and Suitability
Volume Pills is an ingestible dietary supplement intended for adults. Consumers should be aware of the following considerations:
-
People taking prescription medication should discuss supplement use with a qualified healthcare professional.
-
The formula provides 24 mg of zinc per serving, which should be considered alongside zinc obtained from other supplements and dietary sources.
-
Reishi may interact with anticoagulant, antiplatelet or immunosuppressive medications.
-
Seaweed-derived ingredients can vary substantially in iodine content.
-
People with thyroid, liver or other diagnosed medical conditions should obtain professional guidance before using multi-ingredient botanical supplements.
-
Consumers should use the current physical Supplement Facts panel as the definitive source for serving instructions, ingredient information and warnings.
Dietary supplements are not substitutes for clinical diagnosis or medical treatment.
Product Format and Availability
Volume Pills is available to U.S. consumers through VolumePills.com and is supplied in tablet form. Publicly available label information identifies a two-tablet serving containing 24 mg of zinc and a 1,458 mg proprietary botanical blend. Consumers should review the current product label because formulas, serving information and other specifications may change over time.
About Volume Pills
Leading Edge Health is a Canadian health and wellness company established in 2001 and based in Victoria, British Columbia. The company develops and distributes dietary supplements across multiple consumer wellness categories, including products for men’s wellness, healthy aging, personal care and general nutritional support. Volume Pills is one of the dietary supplement products within the company’s portfolio.
Additional company and product information is available through VolumePills.com.
References
-
NIH Dietary Supplement Label Database. Volume Pills by Leading Edge Health. Supplement Facts label.
-
NIH Office of Dietary Supplements. Zinc — Health Professional Fact Sheet.
-
Parcell AC, Smith JM, Schulthies SS, Myrer JW, Fellingham G. Cordyceps Sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance. International Journal of Sport Nutrition and Exercise Metabolism. 2004;14(2):236-242. PMID: 15118196.
-
Memorial Sloan Kettering Cancer Center. Reishi Mushroom.
-
Kapoor MP, Suzuki K, Derek T, Ozeki M, Okubo T. Clinical evaluation of Emblica officinalis in healthy human subjects: health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study. Contemporary Clinical Trials Communications. 2019;17:100499. PMID: 31890983.
-
Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. Journal of the Association of Physicians of India. 2001.
-
Kapoor D, Trikha D, Vijayvergiya R, et al. Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research. 2015.
-
NIH Office of Dietary Supplements. Iodine — Health Professional Fact Sheet.
Media Contact
Kevin Shaw
Product Head, Volume Pills
Leading Edge Health
300 – 1095 McKenzie Avenue
Victoria, BC V8P 2L5
Email: support@volumepills.com
Website:VolumePills.com
These statements have not been evaluated by the U.S. Food and Drug Administration. Volume Pills is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Research referenced in this release concerns individual ingredients studied independently and does not constitute clinical evaluation of the complete Volume Pills formulation or endorsement by the cited researchers, journals or institutions.
